Skip to search formSkip to main contentSkip to account menu

Carisbamate

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
In adult rats, the administration of lithium–pilocarpine (LiPilo) reproduces most clinical and neuropathological features of… 
2015
2015
As reported previously, in the lithium–pilocarpine model of temporal lobe epilepsy (TLE), carisbamate (CRS) produces strong… 
Review
2012
Review
2012
Alcoholism is a complex heterogeneous disease and a number of neurotransmitter and neuromodulator systems have been implicated in… 
2011
2011
Purpose:  To assess the efficacy, safety, and tolerability of adjunctive carisbamate treatment at 800 mg/day and 1,200 mg/day in… 
2009
2009
Background and purpose:  Carisbamate is being developed for adjuvant treatment of partial onset epilepsy. Carisbamate produces… 
2009
2009
Objective.— This study explored the dose‐response relationship of carisbamate administered at doses of 100 mg per day, 300 mg per… 
2009
2009
BACKGROUND Since 1994, when naltrexone (Revia) was approved by the FDA for the treatment of alcoholism, only 2 other drugs… 
2008
2008
Purpose:  Animal models with spontaneous epileptic seizures may be useful in the discovery of new antiepileptic drugs (AEDs). The…